CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.84
2.33%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.86
Open 0.84
1-Year Change -14.29%
Day's Range 0.83 - 0.87
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 22, 2024 0.84 -0.02 -2.33% 0.86 0.87 0.83
Jul 19, 2024 0.86 0.00 0.00% 0.86 0.86 0.83
Jul 18, 2024 0.87 -0.06 -6.45% 0.93 0.93 0.84
Jul 17, 2024 0.92 0.04 4.55% 0.88 0.95 0.88
Jul 16, 2024 0.93 0.04 4.49% 0.89 0.94 0.84
Jul 15, 2024 0.90 -0.02 -2.17% 0.92 0.92 0.86
Jul 12, 2024 0.91 0.03 3.41% 0.88 0.91 0.85
Jul 11, 2024 0.89 0.07 8.54% 0.82 0.89 0.82
Jul 10, 2024 0.80 -0.03 -3.61% 0.83 0.85 0.80
Jul 9, 2024 0.84 -0.04 -4.55% 0.88 0.88 0.84
Jul 8, 2024 0.88 0.00 0.00% 0.88 0.90 0.88
Jul 5, 2024 0.88 -0.03 -3.30% 0.91 0.91 0.87
Jul 3, 2024 0.87 -0.11 -11.22% 0.98 0.98 0.83
Jul 2, 2024 0.98 0.01 1.03% 0.97 0.99 0.97
Jul 1, 2024 0.84 0.05 6.33% 0.79 0.90 0.77
Jun 28, 2024 0.78 -0.11 -12.36% 0.89 0.91 0.78
Jun 27, 2024 0.89 0.00 0.00% 0.89 0.90 0.88
Jun 26, 2024 0.89 -0.01 -1.11% 0.90 0.92 0.88
Jun 25, 2024 0.90 0.00 0.00% 0.90 0.95 0.88
Jun 24, 2024 0.89 0.02 2.30% 0.87 0.93 0.86

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Passage Bio, Inc. Company profile

About Passage Bio Inc

Passage Bio, Inc. is a clinical-stage genetic medicines company. It is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (β-gal) for gangliosidosis (GM1). Its second product candidate, PBFT02, utilizes AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN) for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC) for Krabbe disease. It also has four programs in the research stage: PBML04 for metachromatic leukodystrophy (MLD); PBAL05 for amyotrophic lateral sclerosis (ALS); PBCM06 for Charcot-Marie-Tooth Type 2A (CMT2A), and other.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Passage Bio Inc revenues was not reported. Net loss increased 65% to $185.4M. Higher net loss reflects Research and development increase of 34% to $102.2M (expense), General and administrative increase from $21.1M to $42.8M (expense), Stock-based Compensation in R&D increase from $5.5M to $15.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.91 to -$3.48.

Industry: Bio Therapeutic Drugs

One Commerce Square
2005 Market Street, 39Th Floor
PHILADELPHIA
PENNSYLVANIA 19103
US

People also watch

XRP/USD

0.60 Price
-2.580% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,504.10 Price
+0.720% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

19,822.40 Price
0.000% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

2,407.70 Price
+0.460% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading